Aug 28, 2024 / 01:00PM GMT
Goeran Forsberg - Cantargia AB - Chief Executive Officer
Thank you. It's a pleasure to present Cantargia half year report of what I think has been a very exciting period in the company. So to take you into the highlights, we've had a very good news flow regarding both our clinical programs.
But what I really like to point out here is that Cantargia has taken a major step forward that we now have 2 clinical programs of significance. So the CAN10 program past a number of important milestones during the period. So we are almost completed with the initial sub part of the Phase I trial and that means single dosing.
And we've had the independent safety review on unblinded data that has not picked up any safety concerns. So the safety is obviously very good on CAN10. But we also start to generate the biomarker data, which shows that we have a very potent drug. So for instance, we've documented receptor binding on to the target IL1RAP on immune cells at a relatively early and predictive dose level.
And we also generated strong biomarker data. So we'll present more about that in -- when
Q2 2024 Cantargia AB Earnings Call Transcript
Aug 28, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers